ClinicalTrials.gg
CompletedNCT03301649Updated Dec 20, 2019Results posted

Clinical Endpoint Study of Ivermectin 0.5% Lotion

A Phase 3 interventional study of Generic Ivermectin Lotion 0.5% and Sklice® (Ivermectin) Lotion 0.5% in Head Lice, sponsored by Actavis Inc.. Completed at 1 site in United States. Open to participants aged 6 Months and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-20.

Sponsored by Actavis Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
905
Allocation
Randomized
Ages
6 Months and older
Sex
All
01

Study summary

This clinical study is designed to evaluate the clinical (therapeutic) effect of a generic ivermectin lotion 0.5% (Actavis Laboratories UT, Inc.) relative to that of the Food and Drug Administration (FDA) Reference Listed Drug (RLD) SKLICE® (ivermectin) lotion, 0.5% (Arbor Pharmaceuticals, LLC) in participants with active head lice infestation. Additionally, both the test and reference (that is; the RLD) treatments were tested for superiority to a placebo.

Read the detailed description

Participants will be randomized by household in a 3:3:1 ratio to receive generic ivermectin lotion 0.5%, Sklice (ivermectin) lotion 0.5%, or vehicle lotion.

02

Conditions studied

  • Head Lice
03

In context

Lead sponsor

Actavis Inc. is the lead sponsor of 95 studies on the registry; none are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 10 (91%) have results posted.

First submitted after Actavis Inc. became part of Teva Pharmaceutical Industries, Ltd..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed Institutional Review Board (IRB)-approved form that meets all criteria of current FDA regulations. For participants who are considered minors in the state the study is being conducted (\<18 years in most states), the parent or legal guardian should sign the consent form and the child will be required to sign a participant "assent" form, as appropriate. Participants 11-17 years of age will read and sign an IRB-approved assent form and participants 6-10 years of age will provide verbal assent. Participants 6 months-5 years of age will be exempt from providing assent based on the child's comprehension and cognitive skills.
  2. The participant and/or the participant's parent (legal guardian) is willing to apply the study product as directed, comply with study instructions, and commit to all follow-up visits for the duration of the study.
  3. Male or non-pregnant, non-lactating female, 6 months of age or older.
  4. Females of must not be pregnant or lactating at Visit 1 (Day -1 to 1) (as confirmed by a negative urine pregnancy test with a sensitivity of less than 50 milli-international units/milliliter [mIU/mL] or equivalent units of human chorionic gonadotropin). Women of childbearing potential must agree to the use of a reliable method of . (for example, total abstinence, intrauterine device, a double-barrier method, oral, transdermal, injected, or implanted non-hormonal or hormonal contraceptive) throughout the study. Female participants using hormonal contraceptives should have been on the same product/dosing regimen for at least 28 days before Visit 1 (Day -1 to 1) and should not change this regimen during the study. A sterile sexual partner is not considered an adequate form of birth control.
  5. Index participants (that is, the youngest household member) must have an active head lice infestation, defined as ≥3 live lice (that is, live adults and/or nymphs), at Visit 1 (Day -1 to 1).
  6. Household members participating in the study must have ≥1 live louse (that is; live adults and/or nymphs) at Visit 1 (Day -1 to 1).
  7. All members of the household must be present for examination. Any male head of household who is unable to attend Visit 1 (Day -1 to 1) may be assessed by a second member of the household as being lice free.

Exclusion criteria

Exclusion Criteria:

  1. Females who are pregnant, lactating or planning to become pregnant during the study period.
  2. Participants who do not have a known household affiliation with their household members (that is, do not stay in 1 household consistently, sleeping at 1 place several nights and then at another place or location). Household is defined as living in a shared area or space (for example the same house or apartment unit).
  3. Any infested member of the household is unable or unwilling to be treated with the study product. This includes male heads of household who do not attend Visit 1 (Day -1 to 1) but report infestation with lice.
  4. More than 3 members of the household infested with lice.
  5. Presence of visible skin/scalp condition(s) or open wounds at the application site that are not attributable to head lice infestation and that in the opinion of the Investigator will interfere with safety and/or efficacy evaluations.
  6. Presence of eczema or atopic dermatitis at the application site.
  7. Use of any prescription, over-the-counter, or home remedies for the treatment of head lice within 7 days before Visit 1 (Day -1 to 1).
  8. Use of pediculicides within 4 weeks before Visit 1 (Day -1 to 1).
  9. Use of systemic anti-parasitic agents within four weeks before Visit 1.
  10. Participants with very short (shaved) hair or who are planning to shave head during the study.
  11. Use of any hair dye, bleaches, hair straightening, or permanent wave solution on the hair within 14 days before Visit 1 (Day -1 to 1).
  12. History of allergy or sensitivity to pediculicides or hair care products.
  13. History of any drug or intolerance that, in the opinion of the Investigator, would compromise the safety of the participant or results of the study.
  14. Significant history or current acute or chronic infectious disease, system disorder, Netherton's Syndrome, organ disorder (for example, hepatic or renal impairment) or insufficiency, (from medical treatment or disease), organ transplant, uncontrolled diabetes, uncontrolled hypertension, current ocular condition, or other medical condition that, in the Investigator's opinion, would place the study participant at undue risk by participating in the study.
  15. Participants or non-infested household members who would act as the primary caregiver who are of intellectually competent age but unable to understand the protocol requirements, instructions, and study-related restrictions, the nature, scope, and possible consequences of the clinical study.
  16. Receipt of any drug as part of a research study within 30 days before Visit 1 (Day -1 to 1).
  17. The participant is a member of the study staff or a member of the family of the investigational study staff.
  18. Previous participation in this study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
905 participants (actual)

Study arms

  • Experimental
    Generic Ivermectin Lotion 0.5%

    Infested household participants will administer a single application of up to 117 grams (1 tube) of generic ivermectin 0.5% topical lotion to the dry hair (avoiding contact with eyes) at home on Day 1, leave the lotion on the hair and scalp for 10 minutes, and then rinse off with warm water. Participants will be instructed to wash their hands after application of the study drug, allow hair to dry naturally (pat drying with decontaminated towel is permitted), and to leave hair uncovered after application of the study drug. Following application and rinsing of the study drug, participants are not to shampoo, wash, or rinse their hair or scalp until the Day 2 visit has been completed.

    Drug: Generic Ivermectin Lotion 0.5%

  • Active comparator
    Sklice (Ivermectin) Lotion 0.5%

    Infested household participants will administer a single application of up to 117 grams (1 tube) of Sklice ivermectin 0.5% topical lotion to the dry hair (avoiding contact with eyes) at home on Day 1, leave the lotion on the hair and scalp for 10 minutes, and then rinse off with warm water. Participants will be instructed to wash their hands after application of the study drug, allow hair to dry naturally (pat drying with decontaminated towel is permitted), and to leave hair uncovered after application of the study drug. Following application and rinsing of the study drug, participants are not to shampoo, wash, or rinse their hair or scalp until the Day 2 visit has been completed.

    Drug: Sklice® (Ivermectin) Lotion 0.5%

  • Placebo comparator
    Vehicle Lotion

    Infested household participants will administer a single application of up to 117 grams (1 tube) of vehicle topical lotion to the dry hair (avoiding contact with eyes) at home on Day 1, leave the lotion on the hair and scalp for 10 minutes, and then rinse off with warm water. Participants will be instructed to wash their hands after application of the study drug, allow hair to dry naturally (pat drying with decontaminated towel is permitted), and to leave hair uncovered after application of the study drug. Following application and rinsing of the study drug, participants are not to shampoo, wash, or rinse their hair or scalp until the Day 2 visit has been completed.

    Drug: Vehicle Lotion

Interventions

  • DrugGeneric Ivermectin Lotion 0.5%

    Topical lotion, generic formulation of the brand product.

  • Topical lotion, brand product.

  • DrugVehicle Lotion

    Topical lotion, placebo. Has no active ingredient.

06

What researchers measure

Primary outcomes

  1. Percentage of Index Participants Who Were Considered a Treatment Success: PP Population

    Treatment success was defined as the absence of live lice. Index participant was defined as the youngest household member who was randomized into the study. Therapeutic equivalence evaluation between test (generic ivermectin lotion 0.5%) and reference groups (Sklice \[ivermectin\] lotion 0.5%) was done in this endpoint, hence placebo group was not included.

    Time frame: Day 15 ± 2

  2. Percentage of Index Participants Who Were Considered a Treatment Success: mITT Population

    Treatment success was defined as the absence of live lice. Index participant was defined as the youngest household member who was randomized into the study.

    Time frame: Day 15 ± 2

Secondary outcomes

  1. Percentage of All Randomized (Index + Non-Index) Participants Who Were Considered a Treatment Success: PP Population

    Treatment success was defined as the absence of live lice. Non-index participant: Any household member who agreed to participate in the study but was not the youngest household member. Index participant: The youngest household member who was randomized into the study. Therapeutic equivalence evaluation between test (generic ivermectin lotion 0.5%) and reference groups (Sklice \[ivermectin\] lotion 0.5%) was done in this endpoint, hence placebo group was not included.

    Time frame: Day 15 ± 2

  2. Percentage of All Randomized (Index + Non-Index) Participants Who Were Considered a Treatment Success: mITT Population

    Treatment success was defined as the absence of live lice. Non-index participant: Any household member who agreed to participate in the study but was not the youngest household member. Index participant: The youngest household member who was randomized into the study.

    Time frame: Day 15 ± 2

07

Results

Posted Dec 20, 2019

Participant flow

A total of 912 infested household participants were included and 911 (905 enrolled \[380 index + 525 non-index\] + 6 non-enrolled) were treated. Participants were randomized in 3:3:1 to generic ivermectin, Sklice (ivermectin), or vehicle lotion. 1 participant was considered randomized but not dispensed, so not included in any treatment arm.

Participant flow — Overall Study
MilestoneGeneric Ivermectin Lotion 0.5%Sklice (Ivermectin) LotionVehicle Lotion
Started399400112
Safety population399400112
Modified intent-to-treat(mitt)population372380111
Per-protocol (pp) population345354103
Completed35635627
Not completed434485
Withdrew: Need alternate therapy due to live lice172581
Withdrew: Lost to follow-up11113
Withdrew: Protocol violation011
Withdrew: Withdrawal by subject1040
Withdrew: Other than specified530

Outcome measures

PrimaryPercentage of Index Participants Who Were Considered a Treatment Success: PP Population

Treatment success was defined as the absence of live lice. Index participant was defined as the youngest household member who was randomized into the study. Therapeutic equivalence evaluation between test (generic ivermectin lotion 0.5%) and reference groups (Sklice \[ivermectin\] lotion 0.5%) was done in this endpoint, hence placebo group was not included.

Time frame:
Day 15 ± 2
Reported as:
Number · percentage of participants
Percentage of Index Participants Who Were Considered a Treatment Success: PP Population
percentage of participantsGeneric Ivermectin Lotion 0.5%Sklice (Ivermectin) Lotion
Percentage of Index Participants Who Were Considered a Treatment Success: PP Population90.989.0
Statistical analysis
  • Generic Ivermectin Lotion 0.5% vs Sklice (Ivermectin) Lotion · Difference in percentage of participants: 1.9 · 90% CI -3.9 to 7.8
PrimaryPercentage of Index Participants Who Were Considered a Treatment Success: mITT Population

Treatment success was defined as the absence of live lice. Index participant was defined as the youngest household member who was randomized into the study.

Time frame:
Day 15 ± 2
Reported as:
Number · percentage of participants
Percentage of Index Participants Who Were Considered a Treatment Success: mITT Population
percentage of participantsGeneric Ivermectin Lotion 0.5%Sklice (Ivermectin) LotionVehicle Lotion
Percentage of Index Participants Who Were Considered a Treatment Success: mITT Population91.789.728.6
Statistical analysis
  • Generic Ivermectin Lotion 0.5% vs Vehicle Lotion · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.05 level.)
  • Sklice (Ivermectin) Lotion vs Vehicle Lotion · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.05 level.)
SecondaryPercentage of All Randomized (Index + Non-Index) Participants Who Were Considered a Treatment Success: PP Population

Treatment success was defined as the absence of live lice. Non-index participant: Any household member who agreed to participate in the study but was not the youngest household member. Index participant: The youngest household member who was randomized into the study. Therapeutic equivalence evaluation between test (generic ivermectin lotion 0.5%) and reference groups (Sklice \[ivermectin\] lotion 0.5%) was done in this endpoint, hence placebo group was not included.

Time frame:
Day 15 ± 2
Reported as:
Number · percentage of participants
Percentage of All Randomized (Index + Non-Index) Participants Who Were Considered a Treatment Success: PP Population
percentage of participantsGeneric Ivermectin Lotion 0.5%Sklice (Ivermectin) Lotion
Percentage of All Randomized (Index + Non-Index) Participants Who Were Considered a Treatment Success: PP Population91.690.7
Statistical analysis
  • Generic Ivermectin Lotion 0.5% vs Sklice (Ivermectin) Lotion · Difference in percentage of participants: 0.9 · 90% CI -2.6 to 4.5
SecondaryPercentage of All Randomized (Index + Non-Index) Participants Who Were Considered a Treatment Success: mITT Population

Treatment success was defined as the absence of live lice. Non-index participant: Any household member who agreed to participate in the study but was not the youngest household member. Index participant: The youngest household member who was randomized into the study.

Time frame:
Day 15 ± 2
Reported as:
Number · percentage of participants
Percentage of All Randomized (Index + Non-Index) Participants Who Were Considered a Treatment Success: mITT Population
percentage of participantsGeneric Ivermectin Lotion 0.5%Sklice (Ivermectin) LotionVehicle Lotion
Percentage of All Randomized (Index + Non-Index) Participants Who Were Considered a Treatment Success: mITT Population92.291.325.2
Statistical analysis
  • Generic Ivermectin Lotion 0.5% vs Vehicle Lotion · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.05 level.)
  • Sklice (Ivermectin) Lotion vs Vehicle Lotion · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.05 level.)

Adverse events

Collected over Baseline up to Day 17. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Generic Ivermectin Lotion 0.5%0/399 (0%)0/399 (0%)31/399 (7.8%)
Vehicle Lotion0/400 (0%)0/400 (0%)21/400 (5.3%)
Sklice (Ivermectin) Lotion0/112 (0%)0/112 (0%)1/112 (0.9%)
Most frequent other events
Showing 10 of 25
Most frequent other events
EventGeneric Ivermectin Lotion 0.5%Vehicle LotionSklice (Ivermectin) Lotion
Application site pruritusGeneral disorders9/3998/4001/112
HeadacheNervous system disorders8/3992/4000/112
Eye irritationEye disorders2/3992/4000/112
VomitingGastrointestinal disorders2/3990/4000/112
Viral upper respiratory tract infectionInfections and infestations2/3992/4000/112
CoughRespiratory, thoracic and mediastinal disorders2/3990/4000/112
Application site dysaesthesiaGeneral disorders1/3992/4000/112
Ocular discomfortEye disorders1/3990/4000/112
Abdominal pain upperGastrointestinal disorders1/3990/4000/112
NauseaGastrointestinal disorders1/3991/4000/112

Baseline characteristics

Safety population included all participants who were randomized and received study drug.

Age, Continuous
Age, Continuous(years)Generic Ivermectin Lotion 0.5%Sklice (Ivermectin) LotionVehicle LotionTotal
Mean18.8 ± 15.416.8 ± 13.919.0 ± 14.418.2 ± 14.6
Sex: Female, Male
Sex: Female, Male(Participants)Generic Ivermectin Lotion 0.5%Sklice (Ivermectin) LotionVehicle LotionTotal
Female32232497743
Male777615168
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Generic Ivermectin Lotion 0.5%Sklice (Ivermectin) LotionVehicle LotionTotal
Hispanic or Latino34434693783
Not Hispanic or Latino555419128
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Generic Ivermectin Lotion 0.5%Sklice (Ivermectin) LotionVehicle LotionTotal
American Indian or Alaska Native0202
Asian1112326
Native Hawaiian or Other Pacific Islander2024
Black or African American63110
White377377106860
More than one race3609
Unknown or Not Reported0000
Number of live lice
Number of live lice(live lice)Generic Ivermectin Lotion 0.5%Sklice (Ivermectin) LotionVehicle LotionTotal
Mean4.9 ± 4.44.4 ± 3.54.5 ± 3.14.6 ± 3.7
08

Study locations

1 site
  • Site 1
    Miami, Florida 33134, United States
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Mar 2018, 5 months.

Results were first posted in Dec 2019, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2017
First posted
Oct 4, 2017
StartActual
Oct 7, 2017
Primary completionActual
Mar 12, 2018
CompletionActual
Mar 12, 2018
Results first posted
Dec 20, 2019
Last update
Dec 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03301649
Lead sponsor
Actavis Inc.
Responsible party
Sponsor
First posted
Oct 4, 2017
Start date
Oct 7, 2017
Primary completion
Mar 12, 2018
Completion
Mar 12, 2018
Results posted
Dec 20, 2019
Last update
Dec 20, 2019

Study contacts

Study Director
study director · Actavis Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion